Sulfated polysaccharides target RANK Lys97 to inhibit osteoclast differentiation and reverse osteoporosis
Current osteoporosis treatments fail to balance bone resorption and formation. Here we show engineered 2-N,6-O-sulfated chitosan (26SCS), a synthetic pentasaccharide, restores 115% bone mass (therapeutic) and prevents 66% bone loss, surpassing bisphosphonates by simultaneously suppressing osteoclastogenesis and promoting vascularized osteogenesis.